Lv3
210 积分 2026-01-13 加入
Lipid-Lowering Therapy in the 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia
2天前
已完结
LDL-C–Related Cardiovascular Burden in China 2010 to 2030
2天前
已完结
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
12天前
已完结
Genetics: HMGCR and PCSK9 variants and cardiovascular risk
12天前
已完结
Experimentally Validated SLC6A19 Loss-of-Function Variants Improve Kidney Function and Reduce Progression to Kidney Failure
1个月前
已关闭
Machine learning assessment of pathologic response in lung cancer resections after neoadjuvant therapy - IASLC MPR Project
3个月前
已关闭
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
3个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
3个月前
已完结
Adjuvant Nivolumab vs Observation in Resected Non–Small Cell Lung Cancer
3个月前
已完结
LRP1调控Aβ代谢的机制及其对AD防治研究的启示
3个月前
已完结
皖公网安备34019202002308
